• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[抗高血压药物治疗:我们目前的状况如何?]

[Antihypertensive drug therapy : Where do we stand?].

作者信息

Middeke M

机构信息

Hypertoniezentrum München, Excellence Centre of the European Society of Hypertension (ESH), Herzzentrum Alter Hof, Dienerstr. 12, 80331, München, Deutschland,

出版信息

Internist (Berl). 2015 Mar;56(3):230-9. doi: 10.1007/s00108-014-3570-2.

DOI:10.1007/s00108-014-3570-2
PMID:25707372
Abstract

Antihypertensive drug therapy is one of the most successful medical measures ever, at all levels. The treatment situation in Germany has clearly improved in recent years. Nowadays, a wide range of very effective and well-tolerated hypertensive substances is available. Combination therapy has a long and successful tradition in hypertensive treatment, especially with suitable fixed combinations. Furthermore, the administration of fixed combinations is very beneficial to therapy adherence because it is essentially dependent on the number of drugs to be taken. The value of beta blockers and the double blockade of the renin-angiotensin-aldosterone system are under discussion and the interpretation of corresponding studies must be conducted very carefully. The hypertensive effect of a substance cannot be comprehensively assessed without taking the time of day, the time point of measurement and the time point of intake into consideration. This is particularly important with respect to the effect over 24 h. Optimal antihypertensive therapy must also take into consideration the individual blood pressure rhythm with respect to the dose and dosing intervals. The importance of the central (aortic) blood pressure as target blood pressure will increase.

摘要

抗高血压药物治疗在各个层面都是有史以来最成功的医学措施之一。近年来,德国的治疗情况有了明显改善。如今,有多种非常有效且耐受性良好的降压药物可供使用。联合治疗在高血压治疗方面有着悠久且成功的传统,特别是使用合适的固定复方制剂。此外,服用固定复方制剂对治疗依从性非常有益,因为它基本上取决于需要服用的药物数量。β受体阻滞剂的价值以及肾素 - 血管紧张素 - 醛固酮系统的双重阻断正在讨论中,对相应研究的解读必须非常谨慎。如果不考虑一天中的时间、测量时间点和服药时间点,就无法全面评估一种药物的降压效果。这对于24小时的效果尤为重要。最佳的抗高血压治疗还必须根据剂量和给药间隔考虑个体血压节律。中心(主动脉)血压作为目标血压的重要性将会增加。

相似文献

1
[Antihypertensive drug therapy : Where do we stand?].[抗高血压药物治疗:我们目前的状况如何?]
Internist (Berl). 2015 Mar;56(3):230-9. doi: 10.1007/s00108-014-3570-2.
2
Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.比索洛尔和缬沙坦固定剂量复方治疗高血压的疗效和安全性:一项随机、多中心研究。
Lancet. 2014 May 31;383(9932):1889-98. doi: 10.1016/S0140-6736(14)60614-0.
3
I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.I-ADD 研究:评估在无法用厄贝沙坦 150mg 单药治疗控制的高血压患者中,与厄贝沙坦单药治疗相比,厄贝沙坦/氨氯地平固定剂量联合治疗的疗效和安全性:一项多中心、III 期、前瞻性、随机、开放标签、以盲终点评估的研究。
Clin Ther. 2012 Aug;34(8):1720-34.e3. doi: 10.1016/j.clinthera.2012.07.001. Epub 2012 Jul 30.
4
Twenty-four-hour ambulatory blood pressure evaluation of antihypertensive agents.抗高血压药物的24小时动态血压评估
J Hypertens Suppl. 1997 Dec;15(7):S21-5.
5
Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.血管紧张素转换酶抑制剂或血管紧张素 II 受体阻滞剂联合钙通道阻滞剂降压治疗在预防卒中中的作用。
J Am Pharm Assoc (2003). 2010 Sep-Oct;50(5):e116-25. doi: 10.1331/JAPhA.2010.09234.
6
[Are all antihypertensive drugs renoprotective?].[所有抗高血压药物都具有肾脏保护作用吗?]
Herz. 2004 May;29(3):248-54. doi: 10.1007/s00059-003-2508-6.
7
Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage?新型肾素-血管紧张素-醛固酮系统阻滞剂联合治疗:是否有优势?
Curr Opin Nephrol Hypertens. 2011 Sep;20(5):471-5. doi: 10.1097/MNH.0b013e3283495819.
8
The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.2004年加拿大高血压管理指南:第二部分——治疗
Can J Cardiol. 2004 Jan;20(1):41-54.
9
[Fixed-drug combinations for hypertension].[用于高血压的固定剂量复方制剂]
Nihon Rinsho. 2014 Aug;72(8):1477-84.
10
The therapeutic importance of home blood pressure assessment and combination antihypertensive therapy for achieving target blood pressure control: Ibaraki hypertension assessment trial.家庭血压评估和联合降压治疗在实现目标血压控制方面的治疗重要性:茨城县高血压评估试验。
Hypertens Res. 2010 Dec;33(12):1264-71. doi: 10.1038/hr.2010.175. Epub 2010 Oct 7.

引用本文的文献

1
Exercise Hypertension in Athletes.运动员运动性高血压
J Clin Med. 2022 Aug 19;11(16):4870. doi: 10.3390/jcm11164870.
2
[Management of arterial hypertension].[动脉高血压的管理]
Herz. 2017 Aug;42(5):515-526. doi: 10.1007/s00059-017-4574-1.

本文引用的文献

1
Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials.血压降低对高血压患者结局发生率的影响。1. 随机试验的概述、荟萃分析和荟萃回归分析。
J Hypertens. 2014 Dec;32(12):2285-95. doi: 10.1097/HJH.0000000000000378.
2
Angiotensin-neprilysin inhibition versus enalapril in heart failure.血管紧张素-脑啡肽酶抑制剂与依那普利治疗心力衰竭的比较。
N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.
3
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data.
基于心血管风险的降压治疗:一项个体患者数据分析的荟萃分析。
Lancet. 2014 Aug 16;384(9943):591-598. doi: 10.1016/S0140-6736(14)61212-5.
4
Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people.血压与十二种心血管疾病的发病率:125万人的终生风险、健康生命年损失及特定年龄关联
Lancet. 2014 May 31;383(9932):1899-911. doi: 10.1016/S0140-6736(14)60685-1.
5
Regional variations in hypertension prevalence and management in Germany: results from the German Health Interview and Examination Survey (DEGS1).德国高血压患病率及管理的地区差异:德国健康访谈与检查调查(DEGS1)结果
J Hypertens. 2014 Jul;32(7):1405-13; discussion 1414. doi: 10.1097/HJH.0000000000000211.
6
2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).2014 年成人高血压管理的循证指南:第八届联合国家委员会(JNC 8)任命的专家组报告。
JAMA. 2014 Feb 5;311(5):507-20. doi: 10.1001/jama.2013.284427.
7
Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension.美国高血压学会和国际高血压学会声明:社区高血压管理临床实践指南
J Hypertens. 2014 Jan;32(1):3-15. doi: 10.1097/HJH.0000000000000065.
8
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).2013年欧洲高血压学会(ESH)和欧洲心脏病学会(ESC)动脉高血压管理指南:欧洲高血压学会(ESH)和欧洲心脏病学会(ESC)动脉高血压管理特别工作组
J Hypertens. 2013 Jul;31(7):1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc.
9
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.阿利克仑治疗 2 型糖尿病的心血管和肾脏终点试验。
N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3.
10
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.奥美沙坦治疗 2 型糖尿病患者微量白蛋白尿的延迟或预防。
N Engl J Med. 2011 Mar 10;364(10):907-17. doi: 10.1056/NEJMoa1007994.